NEOADJUVANT BRACHYTHERAPY AND CONCURRENT CHEMORADIOTHERAPY IN CERVICAL CANCER— A REVIEW FROM THE FRENCH CERVICAL CANCER GUIDELINES GROUP - 22/11/26
, Xavier Carcopino 4, Cyrus Chargari 5, the members from the FRENCH CERVICAL CANCER GUIDELINES GROUP 6
Xavier Carcopino 6, Lobna Ouldamer 7, Cyrille Huchon 8, Pauline Asseeva 9, Henri Azaïs 10, Sofiane Bendifallah 11, Jean-Luc Brun 12, Geoffroy Canlorbe 13, Cyrus Chargari 14, Pauline Chauvet 15, Abel Cordoba 16, Hélène Courcier 17, Yohann Dabi 18, Marion de Berti 7, Caroline Diguisto 7, Eva Fuss 19, Thomas Gaillard 20, Tristan Gauthier 21, Witold Gertych 22, Laurence Gladieff 23, Olivier Graesslin 24, Yohan Kerbage 25, Martin Koskas 17, Enora Laas 20, Aymeline Lacorre 21, Vincent Lavoué 26, Lise Lecointre 19, Fabrice Lecuru 27, François Margueritte 21, Alejandra Martinez 28, Paul-Jean Maternowski 12, Patrice Mathevet 29, Imane Menouer 24, Camille Mimoun 8, Anthony Moureau 26, Antoine Netter 6, Charles-André Philip 30, Pascal Rousset 31, Claire Sanson 32, Isabelle Thomassin-Naggara 33, Cyril Touboul 18, Jean Levêque 26Abstract |
Cervical cancer remains a major global health challenge, particularly when diagnosed at a locally advanced stage. This narrative review examines the respective roles of neoadjuvant brachytherapy (NBT), concurrent CRT, and image-guided adaptive brachytherapy (IGABT), together with recent advances in systemic treatment. For locally advanced cervical cancer (LACC), concurrent CISPLATIN-based CRT followed by IGABT remains the standard of care. IGABT enables dose escalation to the primary tumour while limiting exposure of adjacent organs at risk and cannot be adequately replaced by external-beam boost techniques. NBT may be considered for selected patients with node-negative, early-stage disease when treatment de-escalation is appropriate. Although retrospective studies suggest that NBT can facilitate less radical surgery and reduce the need for postoperative radiotherapy, it has not demonstrated a survival advantage over standard treatments. Systemic intensification is reshaping LACC management: the INTERLACE trial demonstrated improved survival with short-course induction chemotherapy before CRT, while KEYNOTE-A18 established PEMBROLIZUMAB administered concurrently with CRT and continued as maintenance therapy as a new option for high-risk disease. Conversely, OUTBACK and CALLA did not support routine adjuvant chemotherapy or DURVALUMAB-based treatment. Optimal outcomes depend on careful patient selection, timely treatment completion, access to high-quality IGABT and interstitial techniques, and multidisciplinary expertise. Expanding access to prevention and evidence-based treatment remains essential to reducing global disparities in cervical cancer outcomes.
Le texte complet de cet article est disponible en PDF.Keywords : Cervical cancer, Neoadjuvant brachytherapy, Concurrent chemoradiotherapy, IGABT, Induction chemotherapy, Immunotherapy
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
